IL7 (Interleukin 7) CTS™ Recombinant Human Protein
Product Image
Gibco™

IL7 (Interleukin 7) CTS™ Recombinant Human Protein

Recombinant IL7 is a bioactive protein intended for use in cell culture applications. IL7 stimulates the proliferation of pre-B and了解更多信息
Have Questions?
货号 CTP0071
价格(CNY)
45,379.00
100 µg
添加至购物车
价格(CNY)
45,379.00
100 µg
添加至购物车
Recombinant IL7 is a bioactive protein intended for use in cell culture applications. IL7 stimulates the proliferation of pre-B and pro-B cells. IL7 also supports the maturation of megakaryocytes. ED50 range = 0.2 to 1 ng⁄mL (Specific Activity: 5.0 x 10^6 to 1.0 x 10^6 units⁄mg), determined by the dose dependent proliferation of human PBMCs. Optimal concentration for individual application should be determined by a dose response assay.
For Research Use Only. Not for use in diagnostic procedures.
规格
活动0.855 ng/ml
生物检测Proliferation of human PBMCs
分类Carrier-Free
内毒素水平< 0.1 ng/μg
表达系统E. coli
基因别名IL-7 (Interleukin 7)
分子量17.5 kDa
产品线Gibco
蛋白质家族Cytokines & Receptors
蛋白质形式Full Length, Recombinant, Ligand
蛋白质子类型Interleukins
纯化方法Gel-Purified
纯度或质量等级95 %
数量100 μg
反应性Human
研究类别Clinical Research, Signal Transduction, Stem Cell Research, Drug Development, Immunology, Oncology
运输条件Wet Ice
适用于(应用)Cell Culture
重组Recombinant
种属Human
Unit Size100 µg
内容与储存
Lyophilized protein can be stored at 2-8°C dessicated. Once reconstituted, store in aliquots at ≤20°C. Avoid multiple freeze⁄thaw cycles.

常见问题解答 (FAQ)

我收到的装重组蛋白的小管看上去是空的。这正常吗?

我们的重组蛋白是以冻干粉的形式运送的。在大多数情况下管中可见蛋白粉末沉淀,有些时候粉末沉淀会脱离原位,粘附在管盖或管壁上。短暂的离心就可将蛋白粉末沉淀收集于管底。不过,并非所有的冻干蛋白均为肉眼可见。在大多数情况下,可见的白色粉末沉淀是原始缓冲溶液中的盐分,管中粉末沉淀大小与重组蛋白的量之间可能并无直接的相关性。如果重组蛋白在冻干前使用了不含盐分的溶剂,则可能并不容易看到粉末沉淀(通常为透明的)。您可通过在SDS PAGE上电泳少量的重溶蛋白溶液来确定蛋白的存在。一般来说,只需在丙烯酰胺胶中上样10ng蛋白,就可清晰地观察到确定预期大小的蛋白条带。

为何我在实验中未检测到重组蛋白的活性?

分析时间至关重要。每一种分析都需要进行条件优化并在响应的峰值时间进行。不同种类的细胞对于生长因子或细胞因子的响应可能会有差异。我们建议推荐用户按照产品手册中的推荐方法,使用相同的指示细胞重复我们的质控(QC)分析,来观察是否能够获得类似的反应结果。此外,血清也可能掩盖细胞的响应情况。对某些类型分析实验可能需要对细胞进行血清饥饿处理。

为何我的重组蛋白没有像产品材料中声称的活性?

如果您按照我们产品插页中的描述进行了测试,但未见到任何反应,则可能由以下几种原因导致:

- 蛋白未按照说明书推荐方式进行溶解。
- 溶解后的蛋白放置时间过长或蛋白发生沉淀。我们推荐您在重新溶解后的3-6个月内使用这些蛋白产品。
- 当重新溶解的蛋白溶液浓度低于0.1 mg/mL时,未添加载体蛋白。低于0.1 mg/mL的工作液应立即使用;我们不推荐长期储存此浓度的蛋白溶液。
- 蛋白溶液经过多次冻融循环或暴露于高温条件下。
- 使用错误类型的容器操作蛋白(某些蛋白非常容易粘附于某些塑料器皿上)。

为何我的重组蛋白不溶解?

溶解性问题可能由操作不当,或未使用推荐溶剂所导致。我们推荐您在打开试剂管前将冻干粉平衡至室温,并使用产品手册中推荐的缓冲液溶解蛋白产品(某些蛋白在低pH缓冲体系中溶解得更好)。请勿配制使用蛋白浓度大于1 mg/mL的浓度溶解蛋白产品。请勿剧烈震荡或混合蛋白溶液。将重新溶解的蛋白置于4°C条件下孵育过夜可能有助于解决任何可溶性问题。

如何确定重组蛋白的生物学活性?

生物分析法常被用来检测某一特定生长因子或细胞因子的生物学活性。在大多数情况下,研究人员一般基于各类指示性细胞——如某些原代细胞或细胞系——来开展生物分析。最为常用的生物分析法包括细胞增殖分析(https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/Cell-Proliferation-Assay.pdf),细胞趋化性分析(https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/Chemotaxis-Assay.pdf),细胞因子生成分析(https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/Cytokine-Production-Assay.pdf)和细胞毒性分析(https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/Cytotoxicity-Assay.pdf)。通常以ED50来表示某一细胞因子的生物活性,该值代表了能够诱发50%最大效应的细胞因子浓度。这一表示效价的方法仅适用于那些剂量效应曲线为S形的细胞因子。

引用和文献 (6)

引用和文献
Abstract
Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system.
Authors:Kotton CN, Lankowski AJ, Scott N, Sisul D, Chen LM, Raschke K, Borders G, Boaz M, Spentzou A, Galán JE, Hohmann EL
Journal:Vaccine
PubMed ID:16824652
CKS257 (Salmonella typhimurium SL1344 DeltaphoP/phoQDelta aroA Deltaasd DeltastrA/strB pSB2131) is a live oral vaccine vector expressing HIV Gag.
Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.
Authors:Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, Ito N, Hasegawa T, Tsukamoto T, Sato N
Journal:Clin Cancer Res
PubMed ID:18980986
CD8(+) CTLs have an essential role in immune response against tumor. Although tumor-associated antigens have been identified in renal cell carcinoma (RCC), few of these are commonly shared and investigated as therapeutic targets in the clinical medicine. In this report, we show that HIFPH3, a member of prolyl hydroxylases that ... More
IL-4 influences the differentiation and the susceptibility to activation-induced cell death of human naive CD8+ T cells.
Authors:Riou C, Dumont AR, Yassine-Diab B, Haddad EK, Sekaly RP
Journal:Int Immunol
PubMed ID:16611649
It is now well established that the cytokine environment influences the activation, differentiation, proliferation and death of T lymphocytes during the primary response to antigen. Using an in vitro model, we investigated the influence of IL-4, added at the onset of TCR stimulation, on phenotypic and functional markers of naive ... More
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition.
Authors:Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI
Journal:Hepatology
PubMed ID:16628627
Hepatitis C virus (HCV) has been reported to elicit B and T cell immunity in infected patients. Despite the presence of antiviral immunity, many patients develop chronic infections leading to cirrhosis, hepatocellular carcinoma, and liver failure that can require transplantation. We have previously described the presence of HLA-A2-restricted, HCV NS3-reactive ... More
Expression of the IL-7 receptor alpha-chain is down regulated on the surface of CD4 T-cells by the HIV-1 Tat protein.
Authors:McLaughlin D, Faller E, Sugden S, MacPherson P
Journal:
PubMed ID:25333710
HIV infection elicits defects in CD4 T-cell homeostasis in both a quantitative and qualitative manner. Interleukin-7 (IL-7) is essential to T-cell homeostasis and several groups have shown reduced levels of the IL-7 receptor alpha-chain (CD127) on both CD4 and CD8 T-cells in viremic HIV+ patients. We have shown previously that ... More